BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28967804)

  • 1. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia.
    Arias-Stella JA; Shah AB; Gupta NS; Williamson SR
    Arch Pathol Lab Med; 2018 Jan; 142(1):64-69. PubMed ID: 28967804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
    Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
    Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
    Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C
    Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
    Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
    Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
    Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
    Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
    Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
    Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
    Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
    Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
    Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
    Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ.
    Straccia P; Fiorentino V; Martini M; Pierconti F
    Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
    Mallofré C; Castillo M; Morente V; Solé M
    Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].
    Zhang W; Jiang YX; Liu Y; Yu WJ; Zhao H; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):433-7. PubMed ID: 24246859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
    Neal DJ; Amin MB; Smith SC
    Diagn Pathol; 2020 May; 15(1):61. PubMed ID: 32456709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis.
    Jones TD; Zhang S; Lopez-Beltran A; Eble JN; Sung MT; MacLennan GT; Montironi R; Tan PH; Zheng S; Baldridge LA; Cheng L
    Am J Surg Pathol; 2007 Dec; 31(12):1861-7. PubMed ID: 18043040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression.
    Ogata DC; Marcondes CA; Tuon FF; Busato WF; Cavalli G; Czeczko LE
    Rev Col Bras Cir; 2012; 39(5):394-400. PubMed ID: 23174791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of atypical papillary urothelial hyperplasia.
    Swierczynski SL; Epstein JI
    Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.